Abstract: The disclosure relates to ultrasonic transducers for therapeutic ultrasound techniques, such as high-intensity focused ultrasound (HIFU) techniques. A challenge is to design ultrasound transducers capable of delivering the required pressure, deep enough in the biological tissue, and with enough precision to deliver the required pressure within the targeted volume of the tissue and without destroying the surrounding tissue. Thus, it is proposed to use a transducer with several ultrasound emitting zones capable of being activated independently. This enables the transducer to deliver the required pressure at a target location that is not aligned with the emission axis.

Abstract: A method for producing or identifying one or several shared cancer epitope(s), as well as the peptides including or being made up of the epitopes identified or produced by the method, expression vectors encoding the peptides, cytotoxic T lymphocytes (CTLs) generated in vitro by stimulation of T cells with the peptides or vectors, CTLs of a subject treated with the peptides or vectors, and engineered T cells expressing T-cell receptors recognizing said peptides. Also, the use of the peptides, expression vectors, CTLs or engineered T cells as a vaccine or a medicament, and in particular, the use of the peptides, expression vectors, CTLs, or engineered T cells for preventing or treating at least one cancer in a subject in need thereof.

Abstract: The present invention relates to indole derivatives of formula (I?) as CK2 inhibitor and pharmaceutical compositions comprising the same. The present invention further relates to the use of such compounds of formula (I) for use for preventing and/or treating a cancer.

Abstract: The disclosure relates to benzoimidazole derivatives, acting as anticancer drugs, as well as pharmaceutical composition containing the compounds. These compounds are able to firstly inhibit the protein/protein interactions of the MAP Kinase Erk, leading to inhibition of proliferation and secondly to induce apoptosis in human cancer cell lines.

Abstract: This computer-implemented method allows assessing the shear elasticity modulus of a flexible tube, such as a blood vessel. In the field of medicine, this allows assessing whether a blood vessel is at risk of breakage or tearing. In the case of an artificial tube to be implanted in a patient's body, this allows verifying that this tube is compatible with the patient's body. The method includes the following further steps: a) obtaining (1002) a first dataset relating to spatiotemporal deformations of the tube; b) detecting and storing (1004) a wall inner surface of the tube and its diameter (D); c) identifying (1006) a number of transverse sections (Sij) of the tube; d) computing (1008) an average particle velocity (Vij) over each section; e) computing (1010) a wave propagation speed (C2) of an antisymmetric wave (W2); f) based on the wave propagation speed (C2) and on the diameter (D), assessing (1012) the shear elasticity modulus (?) of the tube.

Abstract: The invention relates to compounds of formula (I) as follows: (I) wherein X1 and X2, identical or different, are NR5 or a sulfur atom, Y is a group (C1-C10)alkanediyl, Ar1 and Ar2, identical or different, are an aryl group optionally substituted by one or several groups selected from a halogen atom, a (C1-C6) alkyl, —OR1, —NR1R2 and —COOR3? with R1 and R2, independently of each other, are a hydrogen atom, a (C-1-C6) alkyl group or a —COR3 group, R3 and R4? independently of each other, are a hydrogen atom or a (C1-C6) alkyl group, and R5 is a hydrogen atom or a (C1-C6)alkyl group, or a pharmaceutically acceptable salt and/or solvate thereof, in particular for use in cancer treatment.

Abstract: The present invention relates to benzimidazole derivatives and pharmaceutical compositions comprising such benzimidazole derivatives, for use in the treatment or prevention of a histiocytosis or a craniopharyngioma.

Abstract: A compound derived from an aliphatic diamine including at least one pyridine or pyrimidine unit, for use as an anticancer agent, to a therapeutic composition including this compound, to a product including such a compound and another active agent, as well as to such a compound.

Abstract: Methods for identifying HERV-derived T cell epitopes associated with cancer, and peptides that are or that include epitopes identified by the methods, expression vectors encoding the peptides, cytotoxic T lymphocytes (CTLs) of a subject treated with the peptides or vectors and engineered T cells expressing T-cell receptors recognizing the peptides. Also, the peptides, expression vectors, CTLs or engineered T cells as a vaccine or a medicament, and in particular the use of the peptides, expression vectors, CTLs or engineered T cells for use in preventing or treating cancer in a subject in need thereof.

Abstract: A transcriptomic signature based on Human endogenous retroviruses (HERVs) expression to characterize leukemic stem cells. In particular, determining the presence of Leukemic Stem Cells (LSCs) in a patient. In an aspect, determining the presence of, or quantifying, LSCs in a patient. Also, gene-related methods for the identification of high-risk acute myeloid leukemia (AML) patients, methods of predicting response to treatment, methods to evaluate (minimal) residual disease during follow-up, methods to determine relapse risk, and methods of treatment of patients following implementation of the former methods.

Abstract: The use of a transcriptomic signature based on HERVs expression to characterize new AML subtypes, and a method to determine to which AML subtype a patient pertains. The method includes providing relationship between the 9 AML sub-types and HERVs characterized by their specific herv_id and their relationship with one of these AML subtypes, determining from a patient cell sample HERVs expression profile, determining which of the 9 AML subtypes is the most represented based on HERV expression in the cell sample, and attributing to the patient the most represented AML subtype among the 9 AML subtypes. The method allows identifying patients with medium good or bad prognosis and treating the same with a cancer therapy against AML.

Abstract: The present invention relates to a non invasive diagnostic method of pancreatic ductal adenocarcinoma (PDAC) in a subject said method comprising the step of measuring the level of ?ig-h3 protein in a blood sample wherein the serum level of ?ig-h3 is positively correlated with the risk of having a PDAC. By following studies on 2 distinct cohorts of 20 and 104 of PDAC patients, and on PDAC mouse model, the inventors show that ?ig-h3 can be directly detected in the blood sample and ?ig-h3 is expressed very early in tumorigenesis in pancreatic neoplastic lesions. The present invention also relates to antagonist of ?ig-h3 protein, for use in the treatment of PDAC. The inventors found that ?ig-h3 bind directly on CD8+ T cells by reducing their activation and cytotoxic properties. Furthermore, the use of neutralizing ?ig-h3 antibodies in PDAC mouse model, reduced tumor growth by enhancing CD8+ T cell anti-tumoral response.

Abstract: A computer-implemented method for reconstructing a 3D image of a human body part studied of a subject from at least one 2D projection of the human body part studied of the subject and a generative network trained for reconstructing 3D images. The human body part may be the head and/or the neck.

Abstract: A computer-implemented method for generating a registered image (Breg) based on at least one first image of an object compliant with a source imaging modality and on at least one second image of the object compliant with a target imaging modality. The object may include a human body part, and the structures of interest may include stiff regions such as bones, cartilage, or tendons.

Abstract: The invention provides a clonal cell line derived from a liver cancer cell line, preferably derived from a Huh7 hepatocarcinoma cell line, engineered to produce and secrete viral particles containing pregenomic RNA of the hepatitis B virus (HBV), predominantly over DNA of HBV, to calibrate quantitative HBV RNA assays.

Abstract: A therapy apparatus for treating tissue by emission of focused ultrasound waves, including: a creation surface of a pressure field of focused ultrasound waves divided into at least N sectors having segments of asymmetrical concave curve with centres of curvature; centres of curvature asymmetrical to the extent where the centres of curvature are situated at different distances from the plane of symmetry or from at least one of the axis of symmetry and at different depths taken according to the axis of symmetry; the individual axes intersecting between the focal zones and the creation surface or beyond the focal zones such that the beams originating from the sectors intersect to create a focal coverage zone which is off-axis relative to the plane of symmetry or to the axis of symmetry; the sectors of this creation surface creating energy deposit zones with profiles corresponding to the focal coverage zones.

Abstract: The present invention relates to indole derivatives of formula (I?) as CK2 inhibitor and pharmaceutical compositions comprising the same. The present invention further relates to the use of such compounds of formula (I) for use for preventing and/or treating a cancer.

Abstract: A non invasive diagnostic method of pancreatic ductal adenocarcinoma (PDAC) in a subject is provided. The method comprises the step of measuring the level of ?ig-h3 protein in a blood sample wherein the serum level of ?ig-h3 is positively correlated with the risk of having a PDAC. By following studies on 2 distinct cohorts of 20 and 104 of PDAC patients, and on PDAC mouse model, the inventors show that ?ig-h3 can be directly detected in the blood sample and ?ig-h3 is expressed very early in tumorigenesis in pancreatic neoplastic lesions. Also provided is a ?ig-h3 protein, for use in the treatment of PDAC. The inventors found that ?ig-h3 bind directly on CD8+ T cells by reducing their activation and cytotoxic properties. Furthermore, the use of neutralizing ?ig-h3 antibodies in PDAC mouse model reduced tumor growth by enhancing CD8+ T cell anti-tumoral response.

Abstract: Method and system for localizing a region of interest in a medium in which cavitation occurs. Method for localizing a region of interest (R) in a medium (M) in which cavitation occurs, the method comprising the steps consisting in: producing cavitation in the region of interest (R), the cavitation generating an acoustic signal, at each of at least three separate positions, detecting a cavitation signal representative of the acoustic signal of the cavitation, for at least two pairs of cavitation signals, determining a delay between the cavitation signals of each pair of cavitation signals, calculating a localization of the region of interest (R) based on the delays and the positions.

Abstract: The invention relates a fluorescent compound of formula I: wherein A is selected from P, P?O and N; ·R1 is a residue comprising an oxygen atom·R2 is a residue comprising an oxygen atom, or a halogen, ·R3, R4 and R5 are alkyls, possibly substituted or a salt or a solvate thereof. The compound is useful as a fluorescent probe sensitive to membrane fluidity and for diagnosing cancer.